Brief: Monte Rosa Therapeutics Announces First Subjects Dosed In Phase 1 Study Of Mrt-8102, A Nek7-Directed Molecular Glue Degrader For The Treatment Of Multiple Inflammatory Diseases
21/07/2025 12:01
July 21 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O: MONTE ROSA THERAPEUTICS ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 STUDY OF MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INFLAMMATORY DISEASES MONTE ROSA THERAPEUTICS INC - INITIAL RESULTS FROM PHASE 1 STUDY EXPECTED IN H1 2026 MONTE ROSA THERAPEUTICS INC: MRT-8102 PHASE 1 STUDY INITIAL RESULTS ANTICIPATED IN H1 2026 Source text: ID:nGNX9VlSGt Further company coverage: GLUE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million